MRUS
HealthcareMerus N.V.
$90.00
+$0.00 (+0.00%)
Jan 2, 2026
Price History (1Y)
Analysis
Merus N.V. is a biotechnology company operating in the healthcare sector. With a market capitalization of $6.83 billion and revenue of $56.61 million (TTM), it has a moderate scale compared to other companies in its industry. The company's financial health is characterized by significant losses, with a net income of -$381.1 million (TTM) and an operating margin of -794.1%. Merus N.V.'s profitability is further underscored by its negative return on equity (-51.6%) and return on assets (-26.5%). The company's balance sheet shows minimal debt ($12.32 million) but a substantial cash position ($635.93 million), resulting in a debt-to-equity ratio of 1.59. The valuation context for Merus N.V. is marked by negative earnings (Forward P/E: -17.65) and a price-to-book ratio of 8.81, indicating that the company's stock price may not reflect its current financial performance. The revenue growth rate is moderate at 3.2% (YoY), but the lack of dividend yield and payout ratio data precludes further analysis in this area.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Merus N.V.
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
Visit website →Key Statistics
- Market Cap
- $6.83B
- P/E Ratio
- N/A
- 52-Week High
- $97.14
- 52-Week Low
- $33.19
- Avg Volume
- 1.47M
- Beta
- 1.06
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- Netherlands
- Employees
- 260